We noticed you’re blocking ads

Thanks for visiting CRSToday. Our advertisers are important supporters of this site, and content cannot be accessed if ad-blocking software is activated.

In order to avoid adverse performance issues with this site, please white list https://crstoday.com in your ad blocker then refresh this page.

Up Front | Aug 2004

Zyoptix Performs Well Without Nomograms

A contralateral eye study, coupled with the results of the FDA clinical trials of Zyoptix, verifies the platform's superior capabilities.

Stephen G. Slade, MD, FACS

We noticed you’re blocking ads

Cataract & Refractive
Surgery Today

Up Front | Aug 2004

Zyoptix Performs Well Without Nomograms

A contralateral eye study, coupled with the results of the FDA clinical trials of Zyoptix, verifies the platform's superior capabilities.

X

You are now leaving the DURYSTA™ (bimatoprost implant) digital supplement. This link will take you to a site maintained by Bryn Mawr Communications, LLC, who is solely responsible for its content.

We noticed you’re blocking ads

Advertisement - Issue Continues Below

End of Advertisement - Issue Continues Below

Or subscribe on your tablet:

X

Complete a 3-minute survey to help CRST understand your practice patterns during the COVID-19 pandemic and be entered for the chance to win one of 10 $50 Amazon gift cards.

X

You are now leaving the DURYSTA™ (bimatoprost implant) digital supplement. This link will take you to a site maintained by Bryn Mawr Communications, LLC, who is solely responsible for its content.